Vaxcyte Inc. (PCVX)
| Bid | 30.01 |
| Market Cap | 3.95B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -463.93M |
| EPS (ttm) | -3.8 |
| PE Ratio (ttm) | -8.07 |
| Forward PE | -6.57 |
| Analyst | Buy |
| Ask | 32.5 |
| Volume | 1,696,021 |
| Avg. Volume (20D) | 1,970,885 |
| Open | 29.39 |
| Previous Close | 29.12 |
| Day's Range | 28.77 - 30.68 |
| 52-Week Range | 27.66 - 121.06 |
| Beta | 1.26 |
About PCVX
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a co...
Analyst Forecast
According to 9 analyst ratings, the average rating for PCVX stock is "Buy." The 12-month stock price forecast is $145, which is an increase of 373.08% from the latest price.
Stock Forecasts
2 weeks ago · seekingalpha.com
Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying OpportunityVaxcyte, Inc.'s positive results achieved from phase 2 dose-finding study using VAX-24 for the prevention of invasive pneumococcal disease in infants; Further post 4 dose data expected 2nd of 2025. It...
